278 related articles for article (PubMed ID: 25278584)
21. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
22. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
Stein BL; Oh ST; Berenzon D; Hobbs GS; Kremyanskaya M; Rampal RK; Abboud CN; Adler K; Heaney ML; Jabbour EJ; Komrokji RS; Moliterno AR; Ritchie EK; Rice L; Mascarenhas J; Hoffman R
J Clin Oncol; 2015 Nov; 33(33):3953-60. PubMed ID: 26324368
[TBL] [Abstract][Full Text] [Related]
23. Polycythemia Vera: Rapid Evidence Review.
Fox S; Griffin L; Robinson Harris D
Am Fam Physician; 2021 Jun; 103(11):680-687. PubMed ID: 34060791
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations.
Lakey MA; Pardanani A; Hoyer JD; Nguyen PL; Lasho TL; Tefferi A; Hanson CA
Am J Clin Pathol; 2010 Jun; 133(6):942-8. PubMed ID: 20472853
[TBL] [Abstract][Full Text] [Related]
25. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
26. [Recent advances in polycythemia vera treatment].
Edahiro Y
Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
[TBL] [Abstract][Full Text] [Related]
27. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
28. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
29. A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2(V617F).
Tefferi A
Curr Hematol Malig Rep; 2006 Jun; 1(2):81-6. PubMed ID: 20425336
[TBL] [Abstract][Full Text] [Related]
30. Austrian recommendations for the management of polycythemia vera.
Burgstaller S; Buxhofer-Ausch V; Sliwa T; Beham-Schmid C; Gastl G; Geissler K; Melchardt T; Krauth M; Krippl P; Petzer A; Rumpold H; Wölfler A; Gisslinger H
Wien Klin Wochenschr; 2018 Sep; 130(17-18):535-542. PubMed ID: 30027395
[TBL] [Abstract][Full Text] [Related]
31. SOHO State of the Art Updates and Next Questions | Polycythemia Vera: Is It Time to Rethink Treatment?
Mora B; Passamonti F
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):79-85. PubMed ID: 36566109
[TBL] [Abstract][Full Text] [Related]
32. New Therapeutic Approaches in Polycythemia Vera.
Falchi L; Newberry KJ; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S27-33. PubMed ID: 26297275
[TBL] [Abstract][Full Text] [Related]
33. Polycythemia vera: aspects of its current diagnosis and initial treatment.
Silver RT; Abu-Zeinah G
Expert Rev Hematol; 2023 Apr; 16(4):253-266. PubMed ID: 37013802
[TBL] [Abstract][Full Text] [Related]
34. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
35. From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.
Vannucchi AM
Haematologica; 2017 Jan; 102(1):18-29. PubMed ID: 27884974
[TBL] [Abstract][Full Text] [Related]
36. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
37. Treatment of hydroxyurea-resistant/intolerant polycythemia vera: a discussion of best practices.
Kuykendall AT
Ann Hematol; 2023 May; 102(5):985-993. PubMed ID: 36944847
[TBL] [Abstract][Full Text] [Related]
38. Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis.
Thurmes PJ; Steensma DP
Eur J Haematol; 2006 Jul; 77(1):57-60. PubMed ID: 16827884
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera.
Silver RT; Krichevsky S; Gjoni S; Cross NCP
Leuk Lymphoma; 2017 Nov; 58(11):2768-2769. PubMed ID: 28317411
[No Abstract] [Full Text] [Related]
40. The role of a low erythropoietin level in the diagnosis of JAK2 exon 12-mutated polycythemia vera.
Langabeer SE
Blood Cells Mol Dis; 2020 Feb; 80():102377. PubMed ID: 31655393
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]